Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Amid a red alert for a severe heatwave in the UK, the Met Office has also warned of a "pollen bomb" that could significantly affect people with hay fever.

The forecaster said there is no evidence that pollen levels are worse this year, but symptoms may feel more severe due to a combination of high pollen counts and exposure to multiple pollen types.

A 2026 Lancet Countdown in Europe study found that climate change is altering the flowering seasons of plants that release allergenic pollen.

“The combination of the fairly breezy and dry weather is going to bring a lot of pollen into the air this week and for the coming weeks,” Alastair Culham, Professor of Botany at the University of Reading, told The Independent.

“We've seen quite a mixed year so far, a very warm, dry spring which brought pollen on early, and then a series of wet weather which has allowed the grasses to grow exceptionally well. Now the weather has warmed and dried, those grasses are going into flower and the level of pollen from grass is phenomenally high,” he added.

Also read: UK Issues Red Heat-Health Alert: How to Protect Yourself From Extreme Heat

What Is Causing the Pollen Bomb?

Rising temperatures, expected to exceed 30°C on several days this week, are causing trees and grasses to release large amounts of pollen into the air.

“Hay fever symptoms usually appear when the pollen count, which is a measure of the number of grains of pollen in one cubic meter of air, exceeds 50,” the Met Office said.

The agency noted that weather conditions influence how much pollen is released and spread. Humid and windy conditions help pollen travel, while rain can clear it from the air. On sunny days, pollen levels are typically highest in the early evening.

Read To Know: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine

Which Areas Will Be Most Affected?

The Met Office has warned that grass pollen will remain at high levels across England and Wales, with Yorkshire, the Midlands and the North West expected to experience very high counts.

Pollen levels are forecast to be very high across England on June 24, with temperatures reaching around 38°C in some areas.

Northern Ireland and Scotland are also expected to experience medium to high pollen levels throughout the week.

Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries

What Is Hay Fever?

Hay fever is a common allergy that causes sneezing, coughing and itchy eyes.

According to Allergy UK, one in four adults and one in eight children suffer from allergic rhinitis, the medical term for hay fever. Research suggests the number of sufferers is increasing each year.

The Lancet study found that hay fever sufferers now experience symptoms for up to two weeks longer than they did in the 1990s due to climate change.

Symptoms of Hay Fever

• Sneezing and coughing
• Runny or blocked nose
• Itchy, red or watery eyes
• Itchy throat, mouth, nose and ears
• Loss of smell
• Pain around the forehead and sides of the head
• Headache
• Fatigue

How to Protect Yourself

According to the UK NHS, hay fever can last for weeks or months, unlike a cold, which usually resolves within one to two weeks. While there is no cure, symptoms can be managed when pollen levels are high.

Dos

• Apply petroleum jelly around your nostrils to trap pollen
• Wear wraparound sunglasses, a mask or a wide-brimmed hat outdoors
• Shower and change clothes after being outside
• Keep windows and doors closed as much as possible
• Vacuum regularly and dust with a damp cloth
• Use a pollen filter in your car and a HEPA filter in your vacuum cleaner
• Take antihistamine drops, tablets or nasal sprays

Don't

• Cut the grass or walk on the grass
• Spend excessive time outdoors
• Keep fresh flowers inside the house
• Smoke or stay around smoke
• Dry clothes outside
• Let pets indoors if possible, as they can carry pollen inside.

More than 11,000 bottles of the blood pressure medication Chlorthalidone, manufactured in India, have been recalled in the United States, according to the Food and Drug Administration (FDA). This is the second India-made blood pressure drug to be recalled in over a month.

Mumbai-based manufacturer Inventia Healthcare Limited recalled the prescription-only Chlorthalidone Tablets USP, 25 mg on June 5 due to "failed dissolution specifications." This means that the tablets may not break down correctly in the body. The drug is sold under several brand names, including Thalitone and Hygroton, and is distributed in America by New Jersey-based Rising Pharma Holdings.

What Is Chlorthalidone Used For?

Also read: Robert F. Kennedy Jr. Launches Reforms To Speed Up Early Drug Research In US

Chlorthalidone is a diuretic, or "water pill," prescribed to treat high blood pressure and fluid retention associated with conditions such as congestive heart failure, kidney disease, and liver disease.

It works by helping the kidneys eliminate excess water and salt through urine.

The FDA has not yet classified the recall or detailed the potential health consequences for patients.

What Does Dissolution Of A Drug Mean?

Dissolution refers to the process by which a tablet breaks down and releases its active ingredient into the body after it is taken.

A dissolution failure means that, during regulatory testing, the tablets did not dissolve as required. As a result, the active ingredient may not be released properly, potentially reducing the amount of medicine that reaches the bloodstream and works as intended, according to Cardiovascular Business..

Dissolution problems can arise from several factors, including poor formulation design, manufacturing process issues, low-quality raw materials, or stability issues that affect the product over time.

Which Medication Has Been Recalled?

Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine

According to the FDA, 11,460 bottles of Chlorthalidone are included in the recall and carry an expiration date of April 2027.

The recall affects:

• 100-tablet bottles marked with batch RISA24001
• 1,000-tablet bottles marked with batch RISB24002

Second BP Drug Recall

Read More: 4 Indian States Roll Out IV Iron Therapy To Curb Anemia In Pregnant Women: How It Works

The recall follows another FDA recall announced on May 5 involving Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), another prescription blood pressure medication.

A total of 15,696 bottles were recalled due to "failed dissolution specifications: Olmesartan Medoxomil content below specifications."

The medication was also manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC, Parsippany, New Jersey. The recalled bottles carry an expiration date of October 31, 2027.

Both recalls were issued nationwide.

Previous Large-Scale Blood Pressure Drug Recall

The latest recall follows a separate large-scale blood pressure medication recall in October, when manufacturers recalled more than 500,000 bottles of Prazosin Hydrochloride due to contamination concerns.

That recall involved potential contamination with unsafe levels of a cancer-causing chemical, prompting the manufacturer to advise patients to consult their physicians or pharmacists.

The US Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr., today launched a department-wide effort aimed at restoring American leadership in clinical trials and drug testing.

“Today, HHS launched a historic department-wide effort to strengthen America’s clinical research enterprise and ensure the next generation of medical breakthroughs is developed right here in the United States. Under President Trump’s leadership, we are accelerating innovation, expanding research capacity, and ensuring lifesaving discoveries are made in America,” Kennedy wrote in a post on social media platform X.

The Food and Drug Administration (FDA)-led pilot initiative, called Operation TrialBlazer comes at a time when China is gaining ground in the global biotechnology race.

Writing in a Fox News op-ed, Kennedy said, “America should continue to lead the world in clinical research and medical innovation. Instead, we are losing ground.”

He cited a recent study showing that China now conducts more early-stage clinical trials than the United States.

In 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. “Those trends should concern every American,” Kennedy said, stressing that “the future of medicine should be built in America.”

The coordinated department-wide effort aims to accelerate the development of lifesaving treatments in the United States and ensure that patients have access to some of the most innovative therapies in the world.

The initiative brings together multiple HHS divisions, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), and the Office of the Inspector General (OIG).

The effort aims to:

• Eliminate unnecessary delays
• Reduce redundant requirements
• Address regulatory ambiguity that can slow and disincentivize U.S.-based development
• Encourage the broader biomedical research ecosystem to do the same
• Foster a clinical research economy that delivers timely, safe, and effective medical products to support a healthy America

What Is Operation TrialBlazer?

According to the FDA, the initiative will help shorten development timelines by six to 12 months through a series of measures, including pairing drug developers with qualified academic centers and contract research organizations to prepare first-in-human trial applications.

The FDA has also issued draft guidance clarifying that, in many cases, one high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient to provide substantial evidence of effectiveness in support of a drug approval.

Other Programs To Accelerate Drug Research In The US

Read More: Powassan Virus: Deadly Tick-Borne Disease Spreading Across The US; Here's What You Need To Know

In addition to FDA's Operation TrialBlazer, the HHS has proposed initiatives by other divisions such as:

• NIH: Expanding support for well-powered clinical trials while advancing the use of AI, human cell-based models, real-world data, and practical trial tools to speed up therapy development without compromising scientific rigor.
• NCATS: Building on work that led to the first fully personalized CRISPR-based gene-editing treatment to accelerate therapies for rare diseases.
• National Cancer Institute (NCI): Working with cancer centers and researchers to streamline trial activation and improve enrollment in cancer studies.
• Office of the National Coordinator for Health Information Technology (ONC): Exploring ways to connect patients with clinical trials through electronic health records.
• ARPA-H: Advancing programs such as THRIVE and CATALYST to use AI and machine learning to improve trial design, predict safety, optimize dosing, and test multiple therapies simultaneously.
• HHS Office of Inspector General: Seeking public feedback on potential updates to regulations affecting incentives and participation in clinical trials.